XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Preferred stock
Series A Preferred Stock
Preferred stock
Series B Preferred Stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2022       5,101,459      
Beginning balance at Dec. 31, 2022 $ 93,828     $ 1 $ 493,322 $ (394,937) $ (4,558)
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock under Employee Stock Purchase Plan (in shares)       3,584      
Issuance of common stock under Employee Stock Purchase Plan 149       149    
Issuance of vested restricted stock units (in shares)       9,226      
Stock-based compensation expense 2,276       2,276    
Currency translation adjustment (22)           (22)
Unrealized gain on marketable securities 11           11
Net loss (income) (21,663)         (21,663)  
Ending balance (in shares) at Mar. 31, 2023       5,114,269      
Ending balance at Mar. 31, 2023 74,579     $ 1 495,747 (416,600) (4,569)
Beginning balance (in shares) at Dec. 31, 2022       5,101,459      
Beginning balance at Dec. 31, 2022 93,828     $ 1 493,322 (394,937) (4,558)
Increase (Decrease) in Stockholders' Equity              
Currency translation adjustment (69)            
Unrealized gain on marketable securities 11            
Net loss (income) (42,052)            
Ending balance (in shares) at Sep. 30, 2023       5,161,825      
Ending balance at Sep. 30, 2023 60,329     $ 1 501,933 (436,989) (4,616)
Beginning balance (in shares) at Mar. 31, 2023       5,114,269      
Beginning balance at Mar. 31, 2023 74,579     $ 1 495,747 (416,600) (4,569)
Increase (Decrease) in Stockholders' Equity              
Issuance of vested restricted stock units (in shares)       20      
Stock-based compensation expense 2,283       2,283    
Currency translation adjustment (27)           (27)
Net loss (income) (11,387)         (11,387)  
Ending balance (in shares) at Jun. 30, 2023       5,114,289      
Ending balance at Jun. 30, 2023 65,448     $ 1 498,030 (427,987) (4,596)
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock under Employee Stock Purchase Plan (in shares)       2,587      
Issuance of common stock under Employee Stock Purchase Plan 82       82    
Issuance of vested restricted stock units (in shares)       307      
Issuance of common stock, license agreement (in shares)       44,642      
Issuance of common stock, license agreement 1,500       1,500    
Stock-based compensation expense 2,321       2,321    
Currency translation adjustment (20)           (20)
Unrealized gain on marketable securities 0            
Net loss (income) (9,002)         (9,002)  
Ending balance (in shares) at Sep. 30, 2023       5,161,825      
Ending balance at Sep. 30, 2023 $ 60,329     $ 1 501,933 (436,989) (4,616)
Beginning balance (in shares) at Dec. 31, 2023 435,120.513            
Beginning balance at Dec. 31, 2023 $ 296,851            
Increase (Decrease) in Temporary Equity [Roll Forward]              
Issuance of Series A Preferred Stock in connection with private placement and settlement of related forward contract (in shares) 99,140.326            
Issuance of Series A Preferred Stock in connection with private placement and settlement of related forward contract $ 75,197            
Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity (in shares) (534,260.839)            
Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity $ (372,048)            
Ending balance (in shares) at Mar. 31, 2024 0            
Ending balance at Mar. 31, 2024 $ 0            
Beginning balance at Dec. 31, 2023 3,703            
Increase (Decrease) In Temporary Equity, Option, Roll Forward [Roll Forward]              
Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity (3,703)            
Ending balance at Mar. 31, 2024 $ 0            
Beginning balance (in shares) at Dec. 31, 2023 5,397,597 0 0 5,397,597      
Beginning balance at Dec. 31, 2023 $ (440,184) $ 0 $ 0 $ 1 179,062 (614,647) (4,600)
Increase (Decrease) in Stockholders' Equity              
Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity (in shares)   534,260.839          
Transfer of Series A Preferred Stock and options for Series A Preferred Stock to permanent equity 375,751       375,751    
Issuance of common stock upon exercise of options (in shares)       52,558      
Issuance of common stock upon exercise of options 154       154    
Issuance of common stock upon exercise of warrants and Conversion of Series A Preferred Stock to common stock (in shares)       65,681      
Issuance of common stock upon exercise of warrants and Conversion of Series A Preferred Stock to common stock 2,877       2,877    
Stock-based compensation expense 1,431       1,431    
Currency translation adjustment (5)           (5)
Net loss (income) (56,824)         (56,824)  
Ending balance (in shares) at Mar. 31, 2024   534,260.839 0 5,515,836      
Ending balance at Mar. 31, 2024 $ (116,800) $ 0 $ 0 $ 1 559,275 (671,471) (4,605)
Beginning balance (in shares) at Dec. 31, 2023 435,120.513            
Beginning balance at Dec. 31, 2023 $ 296,851            
Ending balance (in shares) at Sep. 30, 2024 0            
Ending balance at Sep. 30, 2024 $ 0            
Beginning balance at Dec. 31, 2023 3,703            
Ending balance at Sep. 30, 2024 $ 0            
Beginning balance (in shares) at Dec. 31, 2023 5,397,597 0 0 5,397,597      
Beginning balance at Dec. 31, 2023 $ (440,184) $ 0 $ 0 $ 1 179,062 (614,647) (4,600)
Increase (Decrease) in Stockholders' Equity              
Currency translation adjustment (6)            
Unrealized gain on marketable securities 0            
Net loss (income) $ (67,171)            
Ending balance (in shares) at Sep. 30, 2024 23,896,525 166,341.592 437,927 23,896,525      
Ending balance at Sep. 30, 2024 $ 752 $ 0 $ 0 $ 2 687,174 (681,818) (4,606)
Beginning balance (in shares) at Mar. 31, 2024 0            
Beginning balance at Mar. 31, 2024 $ 0            
Ending balance (in shares) at Jun. 30, 2024 0            
Ending balance at Jun. 30, 2024 $ 0            
Beginning balance at Mar. 31, 2024 0            
Ending balance at Jun. 30, 2024 0            
Beginning balance (in shares) at Mar. 31, 2024   534,260.839 0 5,515,836      
Beginning balance at Mar. 31, 2024 (116,800) $ 0 $ 0 $ 1 559,275 (671,471) (4,605)
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock upon exercise of options (in shares)       36,451      
Issuance of common stock upon exercise of options 120       120    
Issuance of common stock upon exercise of warrants and Conversion of Series A Preferred Stock to common stock (in shares)   (367,919.247)   12,263,951      
Issuance of common stock upon exercise of warrants and Conversion of Series A Preferred Stock to common stock 0     $ 1 (1)    
Equity offering costs (219)       (219)    
Stock-based compensation expense 1,591       1,591    
Currency translation adjustment 14           14
Net loss (income) 13,836         13,836  
Ending balance (in shares) at Jun. 30, 2024   166,341.592 0 17,816,238      
Ending balance at Jun. 30, 2024 $ (101,458) $ 0 $ 0 $ 2 560,766 (657,635) (4,591)
Ending balance (in shares) at Sep. 30, 2024 0            
Ending balance at Sep. 30, 2024 $ 0            
Ending balance at Sep. 30, 2024 0            
Increase (Decrease) in Stockholders' Equity              
Issuance of Series B Preferred Stock and Common Stock in connection with private placement (in shares)     2,937,903 3,563,247      
Issuance of Series B Preferred Stock and common stock in connection with private placement, net 124,657       124,657    
Issuance of common stock upon exercise of options (in shares)       17,064      
Issuance of common stock upon exercise of options 56       56    
Issuance of common stock upon exercise of warrants and Conversion of Series A Preferred Stock to common stock (in shares)     (2,499,976) 2,499,976      
Stock-based compensation expense 1,695       1,695    
Currency translation adjustment (15)           (15)
Unrealized gain on marketable securities 0            
Net loss (income) $ (24,183)         (24,183)  
Ending balance (in shares) at Sep. 30, 2024 23,896,525 166,341.592 437,927 23,896,525      
Ending balance at Sep. 30, 2024 $ 752 $ 0 $ 0 $ 2 $ 687,174 $ (681,818) $ (4,606)